TABLE 2.
Summary of the present study compared with data from previously published series for C-ANCA determinations by IIF and PR3-ANCA determinations by ELISA during relapsesa
| Assay and author, year (reference) | No. of relapses/no. of patients with relapses | Percent
|
||
|---|---|---|---|---|
| Positive at relapse | Rise in assay value at relapse | Rise in assay value without relapse | ||
| IIF | ||||
| van der Woude et al., 1985 (29) | 9/7 | 100 (9/9)b | NAc | NA |
| Specks et al., 1989 (26) | 3 | 100 (3/3) | 100 (3/3)b | 43 (3/7)d |
| Cohen Tervaert et al., 1989 (6) | 17/12 | 100 (17/17) | 100 (17/17) | 23 (5/22) |
| Halma, 1990 (11A) | 8/6 | 75 (6/8) | 50 (3/6) | 86 (19/22) |
| Maclsaac et al., 1990 (18) | 5/3 | 100 (5/5) | 100 (5/5) | 29 (2/7) |
| Gaskin et al., 1991 (10) | 25/15 | 100 (25/25) | ? (>6/25) | NA |
| Stegeman et al., 1993 (27) | 18/16 | 100 (18/18) | 83 (15/18) | NA |
| Dolman et al., 1993 (9) | 8/8 | 100 (8/8) | 75 (6/8) | 0 (0/6) |
| Kerr et al., 1993 (14) | 45/45 | 87 (39/45) | 20 (9/45) | 44 (7/16) |
| Jeffrey et al., 1994 (13) | 7/5-7 | 100 (7/7) | 100 (7/7) | 63 (12/19) |
| Davenport et al., 1995 (7) | 29/<17 | 72-100 (21-29/29) | 48 (14/29) | 83 (50/64) |
| Kyndt et al., 1999 (16) | 32/13 | 100 (30/30) | 27 (8/30) | 43 (6/14) |
| Boomsma et al., 2000 (3) | 33/33 | 100 (33/33) | 52 (17/33) | 43 (13/30) |
| Girard et al., 2001 (11) | 16-20/16 | 62-85 (10/16-17/20) | NA | NA |
| Towbin et al., 2001 (28) | ?/<14 | NA | 37 | NA |
| Present study | 21/14 | 86 (19/21) | 77 (10/13) | NA |
| Median (range) for IIF | 100 (75-100) | 75 (20-100) | 43 (0-86) | |
| Standard ELISA | ||||
| Dolman et al., 1993 (9) | 8/8 | 75 (6/8) | 75 (6/8) | 0 (0/6) |
| Power et al., 1995 (22) | 4/4 | 75 (3/4) | 25 (1/4) | NA |
| Pettersson and Heigl, 1992 (21) | 7/5 | 86 (6/7) | 75 (3/4) | 40 (2/5) |
| Jayne et al., 1995 (12) | 16/16 | 81-88 (13-14/16) | ≈81 (≈13/16) | ≈24 (≈4/≈17) |
| De'Oliviera et al., 1995 (8) | 23/18 | 87 (20/23) | 50 (10/20) | 33 (5/15) |
| Kyndt et al., 1999 (16) | 32/13 | 100 (30/30) | 33 (10/30) | 41 (7/17) |
| Boomsma et al., 2000 (3) | 33/33 | 100 (33/33) | 81 (27/33) | 29 (11/38) |
| Nowack et al., 2001 (20) | ?/<14 | NA | 32 | NA |
| Arranz et al., 2001 (1) | 8/5 | 38 (3/8) | 38 (3/8) | NA |
| Present study | 21/14 | 86 (19/21) | 77 (10/13) | NA |
| Median (range) for standard ELISA | 86 (38-100) | 50 (25-81) | 31 (0-41) | |
| Capture ELISA | ||||
| Nowack et al., 2001 (20) | ?/<14 | NA | 43 | NA |
| Arranz et al., 2001 (1) | 8/5 | 88 (7/8) | 77 (6/8) | NA |
| Capture ELISA, present study | 21/14 | 100 (21/21) | 100 (13/13) | NA |
a
When the exact figures could not be extracted from the paper, the possible range of data are presented.
b
Values in parentheses are number of relapse incidents assay positive at relapse/total number of relapses.
c
NA, not available.
d
Values in parentheses are the number of patients without a relapse but with a rise in assay value/total number of instances with a rise in assay value.